Aims for significant growth by 2035 through innovation in safety systems, functional materials, and life sciences, with a strong global market presence and robust financial performance. Focuses on new drugs, advanced materials, and shareholder returns, targeting 500 bn yen in sales and 15%+ ROE.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.